Share information
297.90 €
+2.41 %
09/11/2026 16:47
+2.41 %
Open
High
Low
Volume
288.90 €
301.20 €
288.90 €
143,321
Latest News
09-Nov-2026
BE BOLD: BIMZELX[®] (bimekizumab-bkzx) builds on superior joint responses versus SKYRIZI[®] (risankizumab) at Week 16, with clinical improvements sustained through Week 24
09-Nov-2026
BE BOLD: BIMZELX[[®]] (bimekizumab-bkzx) builds on superior joint responses versus SKYRIZI[®] (risankizumab) at Week 16, with clinical improvements sustained through Week 24
09-Nov-2026
ACR 2026: Dapirolizumab Pegol Associated with Greater Treatment Response Rates Versus Placebo in SLE Using Novel Treatment Response Measure
04-Nov-2026
UCB advances its digital antibody engineering program with new Cradle collaboration